about
Associations among 25-year trends in diet, cholesterol and BMI from 140,000 observations in men and women in Northern SwedenPhase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.The Västerbotten Intervention Programme: background, design and implicationsAtherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness.Sex differences in cardiovascular outcome during progression of aortic valve stenosis.High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.Usefulness of natriuretic peptides in primary health care: an exploratory study in elderly patients.Impact of a combined community and primary care prevention strategy on all-cause and cardiovascular mortality: a cohort analysis based on 1 million person-years of follow-up in Västerbotten County, Sweden, during 1990-2006.Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study.Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study.Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.Unequal care for dying patients in Sweden: a comparative registry study of deaths from heart disease and cancer.Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy).A cost-effectiveness study of person-centered integrated heart failure and palliative home care: Based on a randomized controlled trial.Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).The prevalence and characteristics of pruritus in patients with heart failure.Responder to BNP-guided treatment in heart failure. The process of defining a responder.Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.Accuracy of death certificates of cardiovascular disease in a community intervention in Sweden.[Wanted: Politics against heart attacks].Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis.Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study.A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis.Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study.Effect of overweight and obesity on cardiovascular events in asymptomatic aortic stenosis: a SEAS substudy (Simvastatin Ezetimibe in Aortic Stenosis).Telemedicine improves the monitoring process in anticoagulant treatment.Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.Thrombomodulin as a marker for bleeding complications during warfarin treatment.Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden.Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.Sex-related differences in the associations between hyperleptinemia, insulin resistance and dysfibrinolysis.Adjusting parameters of aortic valve stenosis severity by body size.Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
P50
Q21245920-21FFEFD6-48B5-4A28-ABFD-4CEF8CBD4DD2Q33398897-857F75D3-A12A-4586-B02D-7F10A51FA133Q33750597-2F48FECD-3585-47A9-AF41-9B56B40DA0BFQ34153114-0FB74D73-CAB0-4815-9E59-4AB880D5E26BQ35048638-DBF98A7B-3175-4694-AAD5-C326F65D9C41Q35065597-270754A4-C903-48D0-B50C-4D6B6BEC34A3Q36230380-D5564209-FD1A-4679-BC44-9A24069EF001Q36406160-870C0FAB-3480-4827-9672-BF1696F98CC1Q37516634-E1DE4AFF-FF33-4066-90B5-FB2F6CCAD802Q38420241-1BBB15A2-5F11-4E8E-8817-5772D94B79F1Q38428819-9BA37595-3DA2-43AF-8AAC-54693429BABCQ39727938-EB6AAD3F-8664-4D61-AAD8-71F0031AD88CQ39941985-182B28BB-BD52-4DCD-9B0B-1E1C706208AEQ40279326-DF8C9BCE-10B0-4CF6-9837-476F57554622Q41100682-E5E77B4D-8C3D-45DD-8508-DA09A9C68212Q41513065-E10F554E-8E39-4112-8239-74818F7CA8C9Q41604218-56688977-4256-44F8-8EB7-012C0B49E148Q42795700-3C87D797-2442-4C9B-8F2C-030C13D6C462Q43032109-E6E18BEE-5B91-4CA9-861F-82F4F4105EADQ43076173-92FB5B63-D58B-45D3-BE96-3372BB692900Q43089537-0F8F088C-051D-41CF-AE19-821EE7BDF8EEQ43275202-8CBA3F74-3214-48BE-AF58-89428DD753A3Q43407303-D47F888F-2B97-45D6-9BE1-ADBDFBC59F19Q43925506-EB6BFBB3-D74D-4513-B5D5-270F025F602FQ44182707-B812D7CD-F53B-4527-B2B0-1513B27D6142Q44420291-D62244DB-8F74-4EF5-B64E-69325A881CC7Q44425836-82E8BBD6-B538-4728-A765-D7D5D92B97F0Q44513796-6278931A-A11C-440D-8CC3-58DC735F0470Q44551083-261C219D-1D86-4ACA-AC4F-7C6601F4D5A8Q44620783-0AE0B906-7209-4EBC-BF07-A48ECF511CDCQ44717818-270A4B9F-6AF9-4546-A6F4-2EF74E92001DQ44721768-F4793A09-67CD-444D-8E02-14604F4AA798Q45182782-1B54BB23-4690-45EB-8214-F953850CA664Q45930078-7DF1E070-8CC5-46DF-9D93-C204B072E708Q46049646-9BEB8C05-2E49-4BC1-BD6C-15E73E82E3CDQ46055826-9D6DA8C8-4DD9-4C4B-8682-9F8648D61B10Q46239855-E5F3126D-2FF7-4B85-BB6A-9ADBB59F913FQ46333714-EC43DA61-0E71-455C-B70D-624D3860796FQ47174432-E7C410F3-0E06-45BF-872A-1D87B9129E21Q47684334-2017B253-8FEC-459A-B604-122DBB89B76C
P50
description
Zweeds onderzoeker
@nl
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Kurt Boman
@ast
Kurt Boman
@en
Kurt Boman
@es
Kurt Boman
@nl
Kurt Boman
@sl
type
label
Kurt Boman
@ast
Kurt Boman
@en
Kurt Boman
@es
Kurt Boman
@nl
Kurt Boman
@sl
prefLabel
Kurt Boman
@ast
Kurt Boman
@en
Kurt Boman
@es
Kurt Boman
@nl
Kurt Boman
@sl
P106
P108
P21
P27
P31
P496
0000-0002-0350-2132